Voyager Therapeutics (VYGR) Invested Capital (2014 - 2026)

Voyager Therapeutics has disclosed Invested Capital across 13 years of filings, most recently posting $173.7 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $173.7 million, down 36.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $173.7 million (down 36.32% YoY), and the FY2025 annual result was $196.1 million, down 34.59% from the prior year.
• Invested Capital came in at $173.7 million for Q1 2026 at Voyager Therapeutics, down from $196.1 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $340.9 million in Q1 2024 to a low of $59.0 million in Q4 2022.
• The 5-year median for Invested Capital is $217.0 million (2023), against an average of $206.8 million.
• Across the five-year window, Invested Capital tumbled 45.67% in 2022 and surged 300.41% in 2023, its largest moves.
• Voyager Therapeutics' Invested Capital stood at $59.0 million in 2022, then soared by 300.41% to $236.3 million in 2023, then advanced by 26.84% to $299.8 million in 2024, then slumped by 34.59% to $196.1 million in 2025, then dropped by 11.43% to $173.7 million in 2026.
• The last three Invested Capital figures came in at $173.7 million (Q1 2026), $196.1 million (Q4 2025), and $219.8 million (Q3 2025), per Business Quant data.